|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
There is one clinical trial.
Mesenchymal stem cells (MSCs) are of potential help in acute respiratory distress syndrome (ARDS), due to their anti-inflammatory properties. The investigators will analyze the effect of 3 iterative infusions of ex vivo expanded Wharton's Jelly MSCs (total dose 2.10^6/kg) in patients with ARDS due to COVID19, who require mechanical ventilation.
Description: The primary endpoint is the percentage of patients with a PaO2/FiO2 ratio > 200 at D10 of treatment with MSC-GW or placebo.Measure: PaO2 / FiO2 ratio Time: day 10
Description: The evolution of the PaO2/FiO2 ratio between Day 0 (or Day 1) and Day 14 of treatment with MSC-GW or placebo is a secondary endpoint.Measure: respiratory function evolution Time: between Day 0 (or Day 1) and Day 14 of treatment
Description: The effect of WJ-MSC on respiratory assistance is evaluated by the proportion of days without invasive respiratory assistance during the hospital stay and maximum on Day 28 (number of days without invasive respiratory assistance / number of hospital days until Day 28)Measure: respiratory assistance Time: between day 0 (or 1) and day 28 (or last day of hospitalization if before day 28)
Description: Difference in sequential organ failure assessment score (SOFA score), grading 0 (best) to 4 (worst), between Day 5-Day 0 and D14-Day 0Measure: organ failures 1 Time: Day 0 to day 14
Description: number of days without extra-renal treatment treatment / number of days of hospitalization until Day 28)Measure: organ failures 2 Time: day 0 to day 28
Description: number of days without vasopressor supportMeasure: organ failures 3 Time: day 0 to day 28
Description: The duration of stay in intensive care unitMeasure: duration of intensive care Time: day 0 to 90
Description: Cause of death during the stay in intensive care unit and during the hospital stay, on Day 28 and Day 90Measure: Cause of death Time: day 0 to 90
Description: respiratory morbidity on Day 90Measure: respiratory morbidity (TDM, functional respiratory measures) Time: day 90
Description: The evolution of the viral load is evaluated by RT PCR SARS-Cov-2 monitoring on a nasopharyngeal swab (or any other sample) at diagnosis, at Day 7, Day 14, Day 21, Day 28 or on the last day of hospitalisationMeasure: viral load Time: day 0 to day 28 (or last day of hospitalization if before day 28)
Description: - The anti-HLA antibody rate measured on Day 0 (before initiating treatment), on Day 28 and on Day 90Measure: Anti-HLA antibody rate Time: day 0 to day 90
Description: The occurrence of immediate hypersensitivity reactions (chills, hyperthermia associated with hypotension) within 4 to 6 hours of the WJ MSC or placebo infusion.Measure: immediate hypersensitivity reactions Time: day 0, day 3, day 5 (+/- 1day)
Description: The thromboembolic risks monitored biologically by routinely daily monitoring of hemostasis (TP, TCA, Fibrinogen, D-dimers)Measure: thromboembolic adverse events 1 Time: day 0 to day 14
Description: daily monitoring of transthoracic echocardiographyMeasure: thromboembolic adverse events 2 Time: day 0 to day 14
Description: blood cultures in case of T° > 38,5°CMeasure: infectious adverse events Time: day 0 to day 14
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports